RudaCure Inc., une entreprise spécialisée dans le développement de médicaments innovants, a été sélectionnée pour le Grand Prize at 'Core Innovation Korea 2024' hosted by Kookmin Ilbo and Cookie News.
Unlike existing treatments, RudaCure developed a traitement de la sécheresse oculaire RCI001 that shortens drug exposure duration through excellent production lacrymale, récupération des lésions cornéennes, anti-inflammatoire, and effets antioxydants.
RCI001 demonstrates effets thérapeutiques within 24 weeks, and is recognized for overcoming the slow onset and effets secondaires (hyperemia, hemorrhage, élévation de la pression intraoculaire, burning upon instillation) of existing treatments. It also addresses the limitations of steroid-based treatments, enabling long-term use and resolving existing market discomfort.
RudaCure plans to complete national essais cliniques de Phase 1 by 2024, and conduct national and US essais cliniques de Phase 2 in 2025-2026. It also plans to actively pursue global transfert de technologie through overseas données cliniques.
